-
Kenya's economy faces climate change risks: World Bank
-
China's rare earths El Dorado gives strategic edge
-
Wheelchair user flies into space, a first
-
French culture boss accused of mass drinks spiking to humiliate women
-
US Afghans in limbo after Washington soldier attack
-
Nasdaq rallies again while yen falls despite BOJ rate hike
-
US university killer's mystery motive sought after suicide
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
Rome to charge visitors for access to Trevi Fountain
-
Stocks advance with focus on central banks, tech
-
Norway crown princess likely to undergo lung transplant
-
France's budget hits snag in setback for embattled PM
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Trump signs $900 bn defense policy bill into law
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
British energy giant BP extends shakeup with new CEO pick
-
EU kicks off crunch summit on Russian asset plan for Ukraine
-
Sri Lanka plans $1.6 bn in cyclone recovery spending in 2026
-
Most Asian markets track Wall St lower as AI fears mount
-
Danish 'ghetto' tenants hope for EU discrimination win
-
What to know about the EU-Mercosur deal
-
Trump vows economic boom, blames Biden in address to nation
-
ECB set to hold rates but debate swirls over future
-
EU holds crunch summit on Russian asset plan for Ukraine
-
Nasdaq tumbles on renewed angst over AI building boom
-
Billionaire Trump nominee confirmed to lead NASA amid Moon race
-
CNN's future unclear as Trump applies pressure
-
German MPs approve 50 bn euros in military purchases
-
EU's Mercosur trade deal hits French, Italian roadblock
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Warner Bros. Discovery rejects Paramount bid
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
As H5N1 outbreaks continue to rise globally, the need for robust quality control materials has never been greater. ZeptoMetrix's Influenza A H5N1 Quantitative Stock offers laboratories a comprehensive quality control material that requires RNA extraction, unlike traditional naked RNA products. This novel solution includes three encapsulated H5N1 gene segments within a phage-like particle, ensuring realistic validation of extraction, amplification, and detection steps.
BUFFALO, NEW YORK / ACCESS Newswire / June 23, 2025 / ZeptoMetrix® is pleased to announce the launch of NATtrol™ Influenza A H5N1 Quantitative Stock, a groundbreaking advancement in molecular diagnostic quality assurance. Leveraging phage-like particle encapsulated RNA technology, this product sets a new standard for accuracy and reliability in avian influenza (H5N1) detection, addressing critical gaps in laboratories' ability to validate end-to-end testing workflows.
"The ongoing H5N1 pandemic highlighted the urgent need for reliable diagnostic tools," said Dr. Karuna Sharma, PhD, Vice President & Chief Scientific Officer of Antylia Diagnostics division. "This launch represents a significant advancement in diagnostic quality control. By encapsulating RNA within a phage-like particle, we enable labs to have confidence in their results at every step. This is not just innovation; it is vital in the fight against H5N1 and other emerging RNA viruses."
NATtrol Influenza A H5N1 Quantitative Stock (Product Code: 0831198) is NATtrol inactivated to enhance stability and provided with precision quantification at 1,000,000 gene copies/mL of each gene segment, verified by digital PCR (dPCR). The ready-to-use 1 mL format integrates seamlessly with ZeptoMetrix's -STQ product line, streamlining workflow adoption.
More information on how to order and additional ZeptoMetrix products can be found at: www.zeptometrix.com
About ZeptoMetrix®
ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.
Product Page: https://www.zeptometrix.com/us/en/nattrol-influenza-a-h5n1-quantitative-stock-1-x-10-ml-15355
Contact Information
Andrew Zenger
Global Product Manager
[email protected]
(716) 715-7417
SOURCE: ZeptoMetrix
View the original press release on ACCESS Newswire
D.Philippon--CPN